anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.

Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. The reactions due to the steroid component are: elevation of IOP with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.

Secondary Infection: The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroid. The possibility of fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids. Secondary bacterial ocular infection following suppression of host responses also occurs. 

Additional adverse reactions identified from post marketing use include ulcerative keratitis, headache, and Stevens-Johnson syndrome.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common enzymopathies worldwide. Patients with G6PD deficiency are usually asymptomatic throughout their life but can develop acute hemolysis after exposure to free radicals or certain medications. Several studies have shown that serum miRNAs can be used as prognostic biomarkers in various types of hemolytic anemias. However, the impact of G6PD deficiency on circulating miRNA profiles is largely unknown. The present study aimed to assess the use of serum miRNAs as biomarkers for detecting hemolysis in the nonacute phase of G6PD deficiency. Patients with severe or moderate G6PD Viangchan (871G > A) deficiency and normal G6PD patients were enrolled in the present study. The biochemical hemolysis indices were normal in the three groups, while the levels of serum miR-451a, miR-16, and miR-155 were significantly increased in patients with severe G6PD deficiency. In addition, 3D analysis of a set of three miRNAs (miR-451a, miR-16, and miR-155) was able to differentiate G6PD-deficient individuals from healthy individuals, suggesting that these three miRNAs may serve as potential biomarkers for patients in the nonhemolytic phase of G6PD deficiency. In conclusion, miRNAs can be utilized as additional biomarkers to detect hemolysis in the nonacute phase of G6PD deficiency.
Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
The median survival time of first-line chemotherapy for advanced gastric cancer is about one year, and the treatment is still facing the bottleneck. Bevacizumab is an anti-vascular endothelial growth factor (VEGF) targeted therapy drug. It is doubtful whether the low dose of bevacizumab in gastric cancer patients leads to poor curative effect. Now the treatment of advanced gastric cancer has come to the era of immunotherapy. The chemotherapy regimen of daclizumab combined with CAPEOX has been proved to be effective in clinical studies. No clinical study has confirmed the safety and efficacy of CAPEOX regimen combined with sintilimab and bevacizumab.
The invention relates to a drug for curing whooping cough. The whooping cough is a common acute respiratory infectious disease which occurs to children. The pathogenic bacteria of the whooping cough are bordetella pertussis. The whooping cough is characterized in that paroxysmal spasmodic cough can appear, the cough is accompanied with special inspiration roar sounds, and course of the disease is long and can be as long as several weeks even about three months. And then the disease is called whooping cough. According to the drug for curing the whooping cough, air potato, lygodium japonicum sw, and ailanthus are ground together to be powder, and then are refined to pills. According to the drug for curing the whooping cough, the method of moistening lung to arrest cough is adopted to inhibit the bordetella pertussis, a sedation function is achieved, the paroxysmal cough can be relieved, and the drug for curing the whooping cough has the advantages of being convenient to take, and good in curing effect.
The objective of this study is to determine if an intervention designed to reduce sedentary time during a patient's stay in acute care will reduce patient's frailty levels more so than current standard of care. This study will be conducted at a single-centre, but will be a stratified, block randomised control trial. Fifty participants will be recruited within 24 hours of admission to a geriatric acute care unit. Both groups will be fitted with a device that measures sedentary and active time (accelerometer). Participants in the intervention group will have a daily goal for activity and will be provided with real-time feedback on attainment of that goal displayed on a bedside tablet. Participants in the intervention group who do not independently achieve their goal will be assisted in reducing their sedentary time in the afternoon and/or early evening to the maximum level of their ability; this level will be determined in consultation with the healthcare team. The primary outcome is a change in frailty during hospitalization, measured using a 30-item frailty index. The data collection phase is approximately 10 months. Data analysis will take an additional six months (16 months total). Knowledge-users will be involved during all stages of the project. The data generated from this study will enable us to scale up this intervention nationally and internationally. If the intervention is successful, it will warrant a study to implement the intervention as part of standard care. Ultimately, this study will inform guidelines to limit patients' sedentary behaviors in acute care.
PURPOSE:To obtain a nitroglycerin composition containing nitroglycerin, a surfactant and water, having low stimulation to mucous membrane of mouth and excellent in solubility and stability of nitroglycerin. CONSTITUTION:This nitroglycerin composition contains 0.3-1.5wt.% of nitroglycerin, 0.1-13wt.% of a surfactant (e.g. polyoxyethylene castor oil), 60-99wt.% of water and optionally 0 30wt.% of a lower alcohol(e.g. ethanol). This composition is administered at a dose of 0.3-0.6mg as nitroglycerin at a time intraorally, sublingually, intranasally, etc., on the occasion of angina pectoris fit. This composition may be administered to mucous membrane by a dropping pipette directly from a bottle wherein the composition is fractionally placed as it is. However, a spray is preferable from the point of view of stability and handling. The spray is packed in a manner so that 0.15-1.5 mg of nitroglycerin is 'e' a time.
PCOS is one of the most common reproductive endocrine and metabolic diseases in women of adolescence and childbearing age. The prevalence of PCOS in reproductive women is as high as 5-10%, about 50-80% of whom are infertile and need ovulation induction or in vitro fertilization-embryo transfer (IVF-ET). Ovulation/anovulation and hyperandrogenemia are two main features of PCOS. Moreover, about 50-60% of PCOS patients present insulin resistance/hyperinsulinemia. The probability of miscarriage in PCOS is also higher than that of control women. Pregnancy complications in PCOS patients, such as gestational diabetes, preeclampsia, etc., and long-term complications of metabolic syndrome and endometrial cancer are more likely to happen. These not only greatly affect women's reproductive health, but also seriously endanger their psychological status. A large sample of data has shown that the risk of depression in women with PCOS is 3.78 times higher than that of the control women, 5.62 times for anxiety, and 1.78 times for bipolar disorder. With the economic development, more and more attention is paid to the quality of life including their mental health. However, there is few data on the risk factors of depression, anxiety and other psychological disorders in women with PCOS. There is a lack of effective evaluation and prediction systems. It is urgent to establish a risk assessment system for PCOS complicated with psychological diseases through scientific and systematic research, to formulate comprehensive intervention measures to improve the quality of life of women with PCOS and to reduce the incidence of affective disorders.
Patients receive standard of care induction chemotherapy. Beginning 40-180 days after completion of chemotherapy, patients receive rituximab or rituximab and hyaluronidase human or any approved rituximab biosimilar at the approved dose, as in Group I. Patients undergo PET, CT or PET/CT throughout the study. Patients may undergo blood sample collection during screening and on study. Patients also may undergo bone marrow biopsy and aspirate during screening.
The present techniques provide methods and systems to enable a user to securely share user information with a third party. The user information is based on a user data item, but the user data item itself is kept secret and not shared with the third party. The present techniques generate a digital attestation or verifiable credential containing the user information to be shared. An attestation request is received from a third party for at least one fact about a user. At least one user data item associated with the user is obtained and at least one fact from the user data item is determined. This may involve extracting at least one part from the user data item to use as the at least one fact or deriving from the least one part of the user data item the at least one fact. An attestation of the at least one fact is generated, and the generated attestation is transmitted.
Colour vision is an important part of the visual perception. There exist hereditary and acquired forms of colour vision deficiency. Hereditary forms affect 8% of males and 0.4% of females. Acquired forms can occur due to diseases which affect the retina, optic nerve or parts of the brain involved in colour vision such as the optic tract or visual cortex. Early diagnosis of colour vision deficiency is especially important in children to provide prompt aid through parents, teachers or other persons taking care. Moreover colour vision deficiency can be an early sign of beginning and progressive ocular diseases.

Colour vision assessment is part of standard clinical testing in ophthalmology. In children, colour vision assessment can be difficult, as most of the tests were developed for adults. The investigators are going to investigate the suitability of some of these tests for children. It is planned to investigate 40 children without colour vision deficiency and 40 children with a known colour vision deficiency. The data collection will take 1 year.

The study involves an ophthalmologic examination and the assessment of 3 different colour vision tests. All examinations are non-invasive, performed once and last in total about 1 to 1.5 hours. The visual acuity will be assessed by eye charts and refraction measurement followed by a slit lamp examination of the front sections of the eye and an optical examination of the eyeground. The three coulour vision tests are part of the standard repertoire of the Institute for ophthalmology of the University hospital of Zürich. Each colour vision test will be performed once as a test run and twice as a study examination. In the first test the child is asked to recognize known geometrical figures and pictures on charts. The second test involves the recognition of colored caps and the third test is a computer-assisted examination where the child should denote the position of a coloured area on the screen.

In the children with a known optical disease there will be performed additionally an optical coherence tomography to quantify the disease based morphological changes of the retinal layers. Therefore the pupils have to be dilated with the application of specific eye drops medication. This can lead to transient decrease of visual acuity for about 2-4 hours. The child should not drive a bicycle during this time interval. The principal of Optical coherence tomography (OCT) is similar to medical ultrasonics. However in OCT, there are used light waves instead of ultrasound waves, which allow an exact examination of the retinal cell layers.

All the examinations performed in this study are standardized procedures at the Institute of Ophthalmology of the University hospital of Zürich. No risks or harms are expected in relation with the planed examinations. No payment will be asked for the study related examinations. Neither for patients nor for their health insurances arise any additional costs related to the participation in this study.
Access to clean water for irrigation and drinking has long been a global concern. The need for fast, precise, and cost-effective methods to detect harmful bacteria like Enterohemorrhagic Escherichia coli (EHEC) serotype O157:H7 is high due to the potential for severe infectious diseases. Fortunately, recent research has led to developing and utilizing rapid bacterial detection methods. The creation of an aptamer-based biosensor (aptasensor) for the detection of E. coli O157:H7 using label-free aptamers and gold nanoparticles (AuNPs) is described in this study. The specific aptamers that can detect target bacteria are adsorbed on the surface of unmodified AuNPs to form the aptasensor. The detection is performed by target bacterium-induced aptasensor aggregation, which is associated with a red-to-purple color change under high-salt circumstances. We devised a quick and easy method for detecting bacteria using an anti-E. coli O157:H7 aptamer without the need for specialized equipment or pretreatment processes like cell lysis. The aptasensor could identify target bacteria with only as few as 250 colony-forming units (CFU)/ml in 15 min or less, and its specificity based on our test was 100%. This method not only provides a fast direct preparation process but also exhibits remarkable proficiency in promptly identifying the intended target with a heightened level of sensitivity and specificity. Therefore, it can serve as an intelligent tool for monitoring water reservoirs and preventing the transmission of infectious diseases associated with EHEC.
The invention relates to a mixture of products A, B, C, D, comprising a local anaesthetic, butamben, mixed with a eugenate compound from eugenol and zinc oxide powder and a product D, being the red food colourant lycopene from tomato oleoresin. The synergy of said products permits the immediate relief of chronic or acute pain and an improvement in tissue and bone scar formation by replacement after surgical or pathological loss of bone or tissue mass. The colourant is for aesthetic improvement of tissue. The mixture A+B+C+D can be used in the form of a dressing or in the form of a liquid or a spray, in surgery, medicine, dentistry or veterinary care. The preventative and curative properties of said mixture permit the treatment of ulcerative complaints and the complications thereof or proliferative dysplasias in humans and animals. The addition of colourant pigments provides an improved aesthetic effect at the tissue level and the powerful antioxidant effect of lycopene contributes to the improvement in tissue and bone scar tissue formation in humans and in animals.
The safety and effectiveness of amiodarone in pediatric patients have not been established; therefore, the use of amiodarone in pediatric patients is not recommended. In a pediatric trial of 61 patients, aged 30 days to 15 years, hypotension (36%), bradycardia (20%), and AV block (15%) were common dose- related adverse reactions and were severe or life-threatening in some cases. Injection site reactions were seen in 5 (25%) of the 20 patients receiving intravenous amiodarone through a peripheral vein irrespective of dose regimen. 

Amiodarone injection contains the preservative benzyl alcohol [see Description ( 11)] . There have been reports of fatal “gasping syndrome” in neonates (children less than one month of age) following the administration of intravenous solutions containing the preservative benzyl alcohol. Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.
There are no animal or in vitro studies on the combination product fexofenadine hydrochloride and pseudoephedrine hydrochloride to evaluate carcinogenesis, mutagenesis, or impairment of fertility.

The carcinogenic potential and reproductive toxicity of fexofenadine hydrochloride were assessed using terfenadine studies with adequate fexofenadine exposure (area-under-the plasma concentration versus time curve [AUC]). No evidence of carcinogenicity was observed when mice and rats were given daily oral doses up to 150 mg/kg of terfenadine for 18 and 24 months, respectively. In both species, 150 mg/kg of terfenadine produced AUC values of fexofenadine that were approximately 3 times the human AUC at the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR.

Two-year feeding studies in rats and mice conducted under the auspices of the National Toxicology Program (NTP) demonstrated no evidence of carcinogenic potential with ephedrine sulfate, a structurally related drug with pharmacological properties similar to pseudoephedrine, at doses up to 10 and 27 mg/kg, respectively (less than the maximum recommended human daily oral dose of pseudoephedrine hydrochloride on a mg/m2 basis).

In in vitro (Bacterial Reverse Mutation, CHO/HGPRT Forward Mutation, and Rat Lymphocyte Chromosomal Aberration assays) and in vivo (Mouse Bone Marrow Micronucleus assay) tests, fexofenadine hydrochloride revealed no evidence of mutagenicity.

Reproduction and fertility studies with terfenadine in rats produced no effect on male or female fertility at oral doses up to 300 mg/kg/day. However, reduced implants and post implantation losses were reported at 300 mg/kg. A reduction in implants was also observed at an oral dose of 150 mg/kg/day. Oral doses of 150 and 300 mg/kg of terfenadine produced AUC values of fexofenadine that were approximately 4 times the AUC at the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR. In mice, fexofenadine produced no effect on male or female fertility at average dietary doses up to 4438 mg/kg (approximately 15 times the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR based on comparison of the AUCs).
FIELD: gastroenterology. SUBSTANCE: method can be used in operative and conservative treatment of peritonitis. Sorbent is fractionally introduced into digestive canal through probe. Sorbent is shivyr tuin which is employed in the form of 10% suspension in Ringer-Lock solution in amount 500-700 ml for 50-60 min. Through irrigation probe canal, air is forced fractionally in amount 40-50 ml 6 to 12 times in one min. Procedure is performed 3-4 times daily for 2 to 6 days. EFFECT: enhanced enterosorption efficiency and provided additional healing action. 2 dwg, 4 ex
Deferasirox can cause hepatic injury, fatal in some patients. In Study 1, 4 patients (1.3%) discontinued deferasirox because of hepatic toxicity (drug-induced hepatitis in 2 patients and increased serum transaminases in 2 additional patients). Hepatic toxicity appears to be more common in patients greater than 55 years of age. Hepatic failure was more common in patients with significant comorbidities, including liver cirrhosis and multiorgan failure [see Adverse Reactions ( 6.1)] .   
Acute liver injury and failure, including fatal outcomes, have occurred in pediatric deferasirox-treated patients. Liver failure occurred in association with acute kidney injury in pediatric patients at risk for overchelation during a volume-depleting event. Interrupt deferasirox therapy when acute liver injury or acute kidney injury is suspected and during volume depletion. Monitor liver and renal function more frequently in pediatric patients who are receiving deferasirox in the 14 to 28 mg/kg/day range and when iron burden is approaching normal. Use the minimum effective dose to achieve and maintain a low iron burden [see Dosage and Administration ( 2.5), Warnings and Precautions ( 5.6), Adverse Reactions ( 6.1)] . 

  


Measure transaminases [aspartate transaminase (AST) and alanine transaminase (ALT)] and bilirubin in all patients before the initiation of treatment and every 2 weeks during the first month and at least monthly thereafter. Consider dose modifications or interruption of treatment for severe or persistent elevations.   
Avoid the use of deferasirox in patients with severe (Child-Pugh C) hepatic impairment. Reduce the starting dose in patients with moderate (Child-Pugh B) hepatic impairment [see Dosage and Administration ( 2.4), Use in Specific Populations ( 8.7)] . Patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment may be at higher risk for hepatic toxicity.
The invention discloses a manufacturing method of an energy superconductive polymer with treatment functions. The energy superconductive polymer comprises lycopodium clavatum, beautiful sweetgum fruit, frankincense, clematis root, speranskia herb, myrrh, folium artemisiae argyi and Glycine tomentella. The energy superconductive polymer is prepared from pure traditional Chinese medicines by high-tech means, is used simply and does not contain any western medicine components. The manufacturing method utilizes a western medicine manufacturing method. The polymer is prepared from the decolored essence and is pasted to an affected part. When the polymer has no adhesion, through clear cleaning, adhesion is recovered so that the polymer can be reused and has no side effect. When the polymer is pasted to the human body, through the polymer, the human body produces heat so that gloves, trousers, clothes and shoes prepared from the polymer can prevent diseased and warm the human body.
Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.